Enanta Pharmaceuticals Inc. (ENTA) Stock Price Down 2.2%
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) shares were down 2.2% during trading on Thursday . The stock traded as low as $23.10 and last traded at $23.20, with a volume of 102,744 shares changing hands. The stock had previously closed at $23.73.
Several research analysts have commented on ENTA shares. Zacks Investment Research downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 12th. Vetr downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $35.45 price objective for the company. in a research note on Monday, April 25th. Finally, JMP Securities downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 28th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $28.58.
The company has a market cap of $442.46 million and a price-to-earnings ratio of 13.72. The company has a 50-day moving average price of $23.52 and a 200 day moving average price of $27.15.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, May 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by $0.19. During the same period in the previous year, the company posted $1.49 earnings per share. The company had revenue of $13 million for the quarter, compared to the consensus estimate of $16.80 million. The company’s quarterly revenue was down 77.4% compared to the same quarter last year. On average, equities research analysts anticipate that Enanta Pharmaceuticals Inc. will post $1.00 EPS for the current year.
A number of hedge funds have made changes to their positions in ENTA. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Enanta Pharmaceuticals by 114.7% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 32,851 shares of the company’s stock valued at $1,085,000 after buying an additional 17,551 shares in the last quarter. First Trust Advisors LP acquired a new stake in shares of Enanta Pharmaceuticals during the fourth quarter valued at about $1,374,000. EQIS Capital Management boosted its stake in shares of Enanta Pharmaceuticals by 382.0% in the fourth quarter. EQIS Capital Management now owns 44,836 shares of the company’s stock valued at $1,480,000 after buying an additional 35,534 shares in the last quarter. Oxford Asset Management acquired a new stake in shares of Enanta Pharmaceuticals during the fourth quarter valued at about $2,016,000. Finally, GSA Capital Partners LLP boosted its stake in shares of Enanta Pharmaceuticals by 44.3% in the fourth quarter. GSA Capital Partners LLP now owns 80,322 shares of the company’s stock valued at $2,652,000 after buying an additional 24,670 shares in the last quarter.
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).